教員紹介

SDGsへの取り組み

最終学歴

東京大学大学院　医学系研究科　医学博士課程修了

取得学位

博士（医学）　東京大学大学院

所属学会

日本生化学会
動物実験代替法学会

現在の専門分野

腫瘍学、生化学

現在の研究課題

●肝胆膵領域臓器がんに対する新規化学療法の構築に関する研究
●難治性がん疾患の高感度診断に有効な新規マテリアルおよび技術の開発に関する研究

主要研究業績

●肝細胞癌細胞に滞留して抗癌効果を発揮する新規化学療法剤の創出
●肝細胞癌の進行抑制を可能とする新規光線力学的治療法の開発
●肝細胞癌の増殖抑制を誘導する天然薬の探索とその有効成分物質の同定
●薬剤性肝障害の評価を可能とする新規動物評価モデルの構築
●消化器癌細胞にて発現変動する分子種の探索とその腫瘍学的機能の解析

最近の研究業績

1. Takahashi R, Ishizawa T, Inagaki Y, Tanaka M, Ogasawara A, Kuriki Y, Fujita K, Kamiya M, Ushiku T, Urano Y, Hasegawa K. Real-Time Fluorescence Imaging to Identify Cholangiocarcinoma in the Extrahepatic Biliary Tree Using an Enzyme-Activatable Probe. Liver Cancer. 12(6), 590-602, 2023.
2. Ito D, Kawaguchi Y, Inagaki Y, Ito K, Mihara Y, Kaneko J, Tanaka M, Fukayama M, Kokudo N, Hasegawa K. Assessment of liver function-related mRNA expression and fluorescence imaging in outflow-obstructed regions in rats. Surg Today. 53(4), 513-521, 2022.
3. Bae SK, Arita J, Akamatsu N, Maki H, Nishioka Y, Kawahara T, Miyata A, Kokudo T, Nagata R, Mihara Y, Ichida A, Inagaki Y, Kawaguchi Y, Ishizawa T, Kaneko J, Tamura S, Tanaka Y, Moriya K, Hasegawa K. The impact of the covalently closed circular DNA level on recurrence of hepatocellular carcinoma after initial hepatectomy: an analysis of patients with resolved hepatitis B virus infection. HPB (Oxford). S1365-182X(22)01513-1, 2022.
4. Takahashi R, Ishizawa T, Sato M, Inagaki Y, Takanka M, Kuriki Y, Kamiya M, Ushiku T, Urano Y, Hasegawa K. Fluorescence Imaging Using Enzyme-Activatable Probes for Real-Time Identification of Pancreatic Cancer. Front Oncol. 11:714527, 2021.
5. Kobayashi Y, Shindoh J, Nishioka Y, Inagaki Y, Mitsui J, Arita J, Hasegawa K. Germline MICA Polymorphism Is Associated with the Long-Term Outcomes in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg. 24(9), 2137-2139, 2020.
6. Sawakami T, Sun Z, Inagaki Y, Hasegawa K, Tang W, Xu G, Zhang N. The Impact of Apurinic-Apyrimidinic Endonuclease I on Hepatocyte Immuno-Inflammatory Factors and Cell Apoptosis. Biosci Trends. 13(6), 539-545, 2019.
7. Inagaki Y, Kokudo T, Kamiya M, Uno SN, Sato M, Kaneko J, Kokudo N, Urano Y, Hasegawa K. A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green. Sci Rep. 9(1), 3044, 2019.
8. Tanaka M, Shibahara J, Ishikawa S, Ushiku T, Morikawa T, Shinozaki-Ushiku A, Hayashi A, Misumi K, Tanaka A, Katoh H, Sakuma K, Kokudo T, Inagaki Y, Arita J, Sakamoto Y, Hasegawa K, Fukayama M. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma. Virchows Arch. 474(1), 39-46, 2018.
9. Nishioka Y, Shindoh J, Inagaki Y, Gonoi W, Mitsui J, Abe H, Yoshioka R, Yoshida S, Fukayama M, Tsuji S, Hashimoto M, Hasegawa K, Kokudo N. Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases. Dig Dis. 36(6), 437-445, 2018.
10. Xia J, Rong L, Sawakami T, Inagaki Y, Song P, Hasegawa K, Sakamoto Y, Tang W. Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma. Biomed Pharmacother. 99, 921-930, 2018.
11. Shirata C, Kaneko J, Inagaki Y, Kokudo T, Sato M, Kiritani S, Akamatsu N, Arita J, Sakamoto Y, Hasegawa K, Kokudo N. Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress. Sci Rep. 7(1), 13958, 2017.
12. Xia J, Inagaki Y, Gao J, Qi F, Song P, Han G, Sawakami T, Gao B, Luo C, Kokudo N, Hasegawa K, Sakamoto Y, Tang W. Combination of Cinobufacini and Doxorubicin Increases Apoptosis of Hepatocellular Carcinoma Cells through the Fas- and Mitochondria-Mediated Pathways. Am J Chin Med. 45(7), 1537-1556, 2017.
13. Inagaki Y, Matsumoto Y, Tang W, Sekimizu K. Dividing phase-dependent cytotoxicity profiling of human embryonic lung fibroblast identifies candidate anticancer reagents. Drug Discov Ther. 10(4), 195-200, 2016.
14. Xia J, Inagaki Y, Sawakami T, Song P, Cai Y, Hasegawa K, Sakamoto Y, Akimitsu N, Tang W, Kokudo N. Preliminary investigation of five novel long non-coding RNAs in hepatocellular carcinoma cell lines. Biosci Trends. 10(4), 315-9, 2016.
15. Inagaki Y, Matsumoto Y, Ishii M, Uchino K, Sezutsu H, Sekimizu K. Fluorescence imaging for a noninvasive in vivo toxicity-test using a transgenic silkworm expressing green fluorescent protein. Sci Rep. 5, 11180, 2015.
16. Adachi T, Matsumoto Y, Inagaki Y, Sekimizu K. Niemann-Pick disease type C2 protein induces autophagy and inhibits growth in FM3A breast cancer cells. Drug Discov Ther. 9(4), 282-8, 2015.
17. Song P, Inagaki Y, Wang Z, Hasegawa K, Sakamoto Y, Arita J, Tang W, Kokudo N. High Levels of Gamma-Glutamyl Transferase and Indocyanine Green Retention Rate at 15 min as Preoperative Predictors of Tumor Recurrence in Patients With Hepatocellular Carcinoma. Medicine (Baltimore). 94(21), e810, 2015.

受賞

総説
1. Kaneko J, Kokudo T, Inagaki Y, Hasegawa K. Innovative treatment for hepatocellular carcinoma (HCC). Transl Gastroenterol Hepatol. 3, 78, 2018.
2. Xia J, Inagaki Y, Song P, Sawakami T, Kokudo N, Hasegawa K, Sakamoto Y, Tang W. Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus. Biosci Trends. 10(5), 327-336, 2016.
3. Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 22(1), 262-74, 2016.
4. Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol. 21(42), 12059-70, 2015.
5. Inagaki Y, Song P, Tang W, Kokudo N. Cancer-associated carbohydrate antigens for clinical diagnostic markers - its effectiveness and limitations. Drug Discov Ther. 9(2), 129-32, 2015.